🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are escalating worldwide, with estimates suggesting over 82 million new cases each year. Particularly high rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the context of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This approval signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

As per results published in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which combines a dual-drug approach. The study enrolled hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to make available and distribute the drug in many regions with limited resources.

Medical professionals treating patients have expressed hope. Having a one-pill regimen like this is described as a "critical tool" for public health efforts. This is deemed essential to reduce the burden of the illness for individuals and to prevent the spread of untreatable gonorrhoea around the world.